BRIEF-Savara Announces Expanded Access Program For Molgramostim Inhalation Solution For Patients With Autoimmune Pulmonary Alveolar Proteinosis

Reuters
27 Sep 2024

Sept 27 (Reuters) - Savara Inc :

* SAVARA ANNOUNCES EXPANDED ACCESS PROGRAM (EAP) FOR MOLGRAMOSTIM INHALATION SOLUTION (MOLGRAMOSTIM) FOR PATIENTS WITH AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (APAP)

* SAVARA : SAVARA EARLY ACCESS ACCEPTING REQUESTS FROM PATIENTS IN SELECT COUNTRIES IN N.AMERICA & EUROPE, PLANS TO EXPAND THROUGH 2026

* SAVARA INC: PLANS TO COMPLETE SUBMISSION OF A BLA TO FDA FOR MOLGRAMOSTIM IN APAP IN H1 OF 2025

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10